pegunigalsidase alfa
Showing 1 - 25 of 1,367
Fabry Disease Under Enzyme Replacement Therapy With
Recruiting
- Fabry Disease
- Pegunigalsidase-alfa
-
Berlin, Germany
- +7 more
Oct 17, 2023
Fabry Disease Trial (PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeks)
Not yet recruiting
- Fabry Disease
- PRX-102 1 mg/kg every 2 weeks
- PRX-102 2 mg/kg every 4 weeks
- (no location specified)
Jan 24, 2023
Fabry Disease Trial in United States (Pegunigalsidase Alfa)
Available
- Fabry Disease
- Pegunigalsidase Alfa
-
Birmingham, Alabama
- +10 more
Oct 20, 2022
Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly
Enrolling by invitation
- Fabry Disease
- Interview
-
Birmingham, Alabama
- +11 more
Mar 8, 2022
Fabry Disease Trial in Worldwide (pegunigalsidase alfa)
Enrolling by invitation
- Fabry Disease
- pegunigalsidase alfa
-
Birmingham, Alabama
- +14 more
Feb 14, 2022
Fabry Disease Trial in Worldwide (Pegunigalsidase alfa)
Completed
- Fabry Disease
- Pegunigalsidase alfa
-
Birmingham, Alabama
- +20 more
Mar 29, 2022
Fabry Disease Trial in Worldwide (PRX-102 (pegunigalsidase alfa))
Completed
- Fabry Disease
- PRX-102 (pegunigalsidase alfa)
-
Gainesville, Florida
- +6 more
Jan 20, 2022
Fabry Disease Trial in Worldwide (pegunigalsidase alfa)
Enrolling by invitation
- Fabry Disease
- pegunigalsidase alfa
-
Birmingham, Alabama
- +28 more
Feb 14, 2022
Fabry Disease Trial in Worldwide (PRX-102 (pegunigalsidase alfa), agalsidase beta)
Completed
- Fabry Disease
- PRX-102 (pegunigalsidase alfa)
- agalsidase beta
-
Birmingham, Alabama
- +28 more
Oct 12, 2022
Hypophosphatasia Trial in Worldwide (ALXN1850, asfotase alfa)
Not yet recruiting
- Hypophosphatasia
- ALXN1850
- asfotase alfa
-
Hartford, Connecticut
- +29 more
Oct 6, 2023
Hypophosphatasia Trial in Würzburg (Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg)
Recruiting
- Hypophosphatasia
- Ilofotase Alfa, 0.8 mg/kg
- Ilofotase Alfa, 3.2 mg/kg
-
Würzburg, GermanyOsteologie / Klinische Studieneinheit, Orthopädische Klinik - KL
May 26, 2023
Outcomes in Hospitalised Patients Treated With Ondexxya
Not yet recruiting
- Hemorrhage
- Andexanet alfa
- (no location specified)
Jun 12, 2023
Urgent Surgery Trial (Andexanet alfa, Usual Care)
Not yet recruiting
- Urgent Surgery
- Andexanet alfa
- Usual Care
- (no location specified)
Jun 21, 2023
Efanesoctocog Alfa on Long-term Joint Health in Hemophilia A
Not yet recruiting
- Hemophilia A
- Efanesoctocog Alfa BIVV001
- (no location specified)
Jun 19, 2023
Glycogen Storage Disease Type II Pompe Disease Trial in Worldwide (GZ402666)
Completed
- Glycogen Storage Disease Type II Pompe Disease
-
Phoenix, Arizona
- +16 more
Dec 14, 2022
Multiple Myeloma Trial in Worldwide (Modakafusp alfa, Lenalidomide, Bortezomib)
Recruiting
- Multiple Myeloma
- Modakafusp alfa
- +5 more
-
Little Rock, Arkansas
- +53 more
Jan 12, 2023
Anemia Trial in Anyang-si (Ferric Derisomaltose Injection, Darbepoetin Alfa Injection)
Recruiting
- Anemia
- Ferric Derisomaltose Injection
- Darbepoetin Alfa Injection
-
Anyang-si, Korea, Republic ofHallym University Medical Center
Mar 13, 2023
Damoctocog Alfa Pegol, How it is Used in Every Day Practice, and
Not yet recruiting
- Hemophilia A
- No intervention
-
Sacramento, California
- +2 more
Jan 10, 2023
Glycogen Storage Disease Type II-Pompe's Disease Trial in Worldwide (Avalglucosidase alfa (GZ402666), Alglucosidase alfa
Active, not recruiting
- Glycogen Storage Disease Type II-Pompe's Disease
- Avalglucosidase alfa (GZ402666)
- Alglucosidase alfa (GZ419829)
-
Valhalla, New York
- +9 more
May 3, 2022
Glycogen Storage Disease Type II Trial in Worldwide (Alglucosidase alfa GZ419829)
Recruiting
- Glycogen Storage Disease Type II
- Alglucosidase alfa GZ419829
-
Leuven, Belgium
- +8 more
Jan 17, 2023
Cognitive Remote Assessment Using FLAME (CRA-FLAME)
Enrolling by invitation
- Cognitive Impairment
- Remote cognitive testing
-
Barcelona, SpainBarcelonaBeta Brain Research Center
Nov 17, 2022